Search

Displaying results 1481 - 1490 of 4692 in total
  1. Drug

    Dydrogesterone

    go.drugbank.com/drugs/DB00378
    ApprovedInvestigationalWithdrawn

    A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

  2. Drug

    Meprobamate

    go.drugbank.com/drugs/DB00371
    ApprovedIllicit

    It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. … Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated).

  3. Drug

    MK-3577

    go.drugbank.com/drugs/DB14957
    Investigational

    MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).

  4. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

  5. Drug

    Estazolam

    go.drugbank.com/drugs/DB01215
    ApprovedIllicitInvestigational

    A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.

  6. Drug

    Topiramate

    go.drugbank.com/drugs/DB00273
    ApprovedInvestigational

    [A175249] It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. … [A175249] Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.[A188330]

    Products: NABIAN-K
  7. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    Although this regimen is effective in up to 60% of patients, patients with relapsed or refractory DLBCL have poor outcomes. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.

  8. Drug

    Cyproheptadine

    go.drugbank.com/drugs/DB00434
    ApprovedInvestigational

    Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in ...

  9. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019. … [L34485] The use of semaglutide in weight management is also approved by Health Canada [L39347] and the EMA.

  10. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain